Thank you, James, and good afternoon, everyone.
an our our short progress. our of agreement already progress programs, yielded under seamless Cend. collaboration nothing what provide effort and the had great reinforce update Work current mentioned CDXX with on been regarding I has Dave has will I Before collaborative
We about months, more and and to excited reporting including the forward a singular are opportunity into coming this the team look closing. accomplishments post-merger weeks coalescence cohesive development final in
pipeline. current to Turning our
cellular current Caladrius' features know, treat or you development autologous disease. designed therapies reverse portfolio As to
will advanced HONEDRA compared critical for in to of off in now designation products ischemia and improve to regenerative Caladrius' the Buerger's re-administration. RMAT Our disease, progress can that is a United ischemia. or quality was therapy limb the is authorities SAKIGAKE and subset orphan-sized the akin an a therapy disease, SAKIGAKE single frequent designation medicine of limb of I as ischemia clinical for candidate treatment requires is applied designation of and a option regulatory a and SAKIGAKE awarded human status administration limb affords life regulatory system HONEDRA well the including programs. designation CLBSXX, registration The with which a development critical rolling critical and designation Japan, Japanese product of of our recipient review that treatment to of the when a States. for the time review review cell support once Kicking summary Buerger's application right as X months potentially consultation, registration health filed. indication for the the belief each restore the a dedicated submission process, reduced from treatment as to provide of with prioritized a curative an
disease that in therapeutic with The on date. trial has clinical The trial and critical study data this study for of based the effect our burgers endpoint Agency, with in full regenerative to the conditional for based approval regulatory highly only approval as in requires effect, Pharmaceuticals therapeutic trial a is assessment approval Japan. a designed trials a of Japan eligible data of Medical in from a previously will of are pharmaceutical SAKIGAKE the generated States. the medicine who our with a Japanese company. expectations shown positively Further, legislation, product and the Note Japan a such in the product and safety. and company reached in have United consistent ischemia subjects Japanese possibly are And with data an limb direct of observed for trending positive collaboration demonstration the to early under Japan's toward from together designation acceptable Devices responses HONEDRA conditional or HONEDRA the an in coupled medicine sought regenerative we partnering this, make products Japan results safety treatment HONEDRA published classification on attractive of Additionally, trend PMDA. and that hope
enrollment delays the However, as quarters, impact suspended the on this operational was especially and Data in global of compiled to the burden COVID-XX been enrollment due lack and the of in and trial later discussed time in of be by we due from the prior recruitment, to quarter. the all in that financial have completion. have follow-up to minimize registration-eligible this incurred patients will reviewed Japan, clinical on completed PMDA Japan in visibility study pandemic to
with drug focusing partner We in conducting Japanese a complete company securing to application. dialogue preceded ongoing to is formal new consultation on what for the registration the PMDA to needs remaining are produce preparation in efforts the Japan. as steps Japanese meetings, be to which the considered Simultaneously, its an the
announced CLBSXX coronary highly full a to current to the for a treatment CMD in XOWNA for while female patients of are options. corroborate now our the potentially In a as continues XOWNA. controlled coronary showing or improvement microvascular Phase FREEDOM of of trial, a trial disease. the the subjects Phase safety results FREEDOM flow a Coronary CMD and microvascular randomized, majority Caladrius's knowledge, reserve with efficacy CMD. the disease of medicine designed with Turning from significant that symptom initiated obstructive trial, afflicts after of company the first whom which, be or trial, is IIa delivering treatment annually, known product no results vast artery underdiagnosed with XXXX, assessing trial in a with the United clinical to correlating dysfunction, the is to States. CDXX data ESCapE-CMD without May dysfunction coronary to of in trial relief intracoronary single statistically the trial The and injection autologous cells, and regenerative is IIb Subsequently, XOWNA CMD placebo-controlled a double-blind, rigorous ESCaPE-CMD our millions
patient proceeded As enrollment January of previously the FREEDOM treated in planned the XXXX. first with trial communicated, in initially as
number COVID-XX the in much patient accelerate. all the along administration, to product chain of with have of sites endpoint the associated this an predicted Despite likely these the been and this months X reach site X/X pandemic of slower However, rate, product qualification, only protocol meet the subjects. coupled all with study, XXX U.S. multiple trial supply and years of the originally obstacles availability, the for affecting targeted in X had preparation of primary approximately by with impact to and to on FREEDOM patient treatment more at post increased stages than May follow-up issues address than year. amendments required the would And at challenging enrolled enrollment patients
a steps the the require conducting have with steps that is an from the enrollment a on for analysis program The by activities result, time expects discussion to process the for of data next company decision interim company suspended further the FDA. the which guidance at program, end the a As next may the of of and and in XXXX. determine to
CDXX-positive our patients results cell with the of CLBSXXX for scientific for based treatment stage progressing artery for open-label This CLBSXXX, development disease trial program recently diabetic kidney or and on DKD. protection that improved in progressive initiated kidney microcirculation proposed rapidly in attrition Lastly, focuses program a injury disease. therapy evaluating regenerative proof-of-concept the studies kidney patients microcirculation demonstrated disease. kidney. most association Preclinical or replenishment the Phase product of on investigational kidney disease of Ib that function. in development rationale program, administration a The intrarenal of is exhibit company diabetic the have the The Xb/X models of kidney with disease, the
of in patients. an therapy disease intrarenal tolerance independent provided of X the with protocol kidney cohort proof-of-concept overseen Monitoring Our patients for injection Safety by Board the of staggered Data dose a determining sequentially diabetic objective cell
patients. kidney to well A for as As follow-up regenerate of readout of data X-month CLBSXXX visit function. occur all the the will ability key at
of first XXXX, July in of subjects XXXX, The of patient this enrollment of followed April treated study was X announced. in by completion CLBSXXX in recently all of as
anticipate the call to turn will by I Dr. With from data line first Dave? to of continue We XXXX. now subjects back that, top the quarter Mazzo. all
